Kala Bio, Inc. (KALA)
0.57
+0.03
(+5.97%)
USD |
NASDAQ |
Sep 09, 13:39
Kala Bio Total Liabilities (Quarterly) : 1.538M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.538M |
| March 31, 2026 | 1.557M |
| December 31, 2025 | 2.494M |
| September 30, 2025 | 33.69M |
| June 30, 2025 | 39.26M |
| March 31, 2025 | 42.54M |
| December 31, 2024 | 43.15M |
| September 30, 2024 | 47.22M |
| June 30, 2024 | 47.89M |
| March 31, 2024 | 46.37M |
| December 31, 2023 | 48.44M |
| September 30, 2023 | 49.90M |
| June 30, 2023 | 49.01M |
| March 31, 2023 | 48.76M |
| December 31, 2022 | 67.85M |
| September 30, 2022 | 86.67M |
| June 30, 2022 | 116.53M |
| March 31, 2022 | 116.86M |
| December 31, 2021 | 122.62M |
| September 30, 2021 | 132.34M |
| June 30, 2021 | 131.19M |
| March 31, 2021 | 120.04M |
| December 31, 2020 | 121.61M |
| September 30, 2020 | 119.07M |
| Date | Value |
|---|---|
| June 30, 2020 | 116.57M |
| March 31, 2020 | 117.02M |
| December 31, 2019 | 124.63M |
| September 30, 2019 | 117.96M |
| June 30, 2019 | 117.75M |
| March 31, 2019 | 114.65M |
| December 31, 2018 | 115.99M |
| September 30, 2018 | 29.14M |
| June 30, 2018 | 27.50M |
| March 31, 2018 | 24.72M |
| December 31, 2017 | 26.45M |
| September 30, 2017 | 24.83M |
| June 30, 2017 | 17.62M |
| March 31, 2017 | 16.22M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | 14.24M |
| September 30, 2015 | 13.86M |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 8.46M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 10.58M |
| Shareholders Equity (Quarterly) | 9.044M |
| Current Ratio | 6.880 |
| Net Debt Paydown Yield | 19.34% |